Litigation
Jun. 10, 2011
Amylin Loses Bid for Injunction
San Diego-based Amylin Pharmaceuticals Inc. lost its bid to win a preliminary injunction that would block Eli Lilly and Co. from using the same sales force to sell Amylin's diabetes drug Byetta and German drugmaker Boehringer Ingelheim's competing medication Tradjenta.




Daily Journal Staff Writer
San Diego-based Amylin Pharmaceuticals Inc. lost its bid to win a preliminary injunction that would block Eli Lilly and Co. from using the same sales force to sell Amylin's diabetes drug Byetta and German drugmaker Boehringer Ingelheim's competing medication Tradjenta. Amylin filed a sealed lawsuit against Lilly on May 16 alleging Indianapolis-based Lilly breached a 2002 contract to market Byetta and...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In